Full Papers
Evaluation of the predictive validity of the ASAS axial spondyloarthritis criteria in the DESIR cohort
B. Meghnathi1, A. Saraux2, M. Dougados3, A. Moltó4
- Paris Descartes University, Medicine Faculty; APHP, Rheumatology B Department, Cochin Hospital, Paris; INSERM (U1153): Clinical Epidemiology and Biostatistics PRES Sorbonne Paris-Cité, France. dr.bhowmik@yahoo.co.in
- Rheumatology Department, Centre National de Référence des Maladies Auto-Immunes Rares (CERAINO), Cavale Blanche University Hospital, Brest; UMR 1227, Lymphocytes B et Autoimmunité, Université de Brest, Inserm, CHU Brest, LabEx IGO, Brest, France.
- Paris Descartes University, Medicine Faculty; APHP, Rheumatology B Department, Cochin Hospital, Paris; INSERM (U1153): Clinical Epidemiology and Biostatistics PRES Sorbonne Paris-Cité, France.
- Paris Descartes University, Medicine Faculty; APHP, Rheumatology B Department, Cochin Hospital, Paris; INSERM (U1153): Clinical Epidemiology and Biostatistics PRES Sorbonne Paris-Cité, France.
CER11631
2019 Vol.37, N°5
PI 0797, PF 0802
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 30873948 [PubMed]
Received: 19/08/2018
Accepted : 03/12/2018
In Press: 07/03/2019
Published: 29/08/2019
Abstract
OBJECTIVES:
To evaluate the predictive validity of the Assessment of SpondyloArthritis international Society (ASAS) axial spondyloarthritis (axSpA), Amor, European Spondylarthropathy Study Group (ESSG) and modified New York (mNY) classification criteria.
METHODS:
Patients from the DESIR cohort (inflammatory back pain suggestive of axSpA for >3 months but <3 years duration), followed for up to 5 years. Positive predictive value (PPV) of the set of criteria collected at baseline (ASAS, and its arms, Amor, ESSG and mNY: fulfilled/not fulfilled) were tested against the rheumatologist’s axSpA diagnosis (fulfilled/not fulfilled) after 5 years of follow-up.
RESULTS:
In total, among the 708 patients included in the DESIR cohort at baseline, data on rheumatologist’s diagnosis at 5 years was available in 411 patients; amongst them, 352 (85.6%) had an axSpA diagnosis according to the rheumatologist; 268 patients fulfilled the ASAS axial SpA (axSpA) criteria at baseline and of these, 245 were diagnosed as SpA after 5 years follow-up (PPV: 91%). The PPV of the ASAS “imaging” arm and “clinical” arm was 97% and 82%, respectively. Other criteria also showed similar PPV – Amor (91%), ESSG (90%) and mNY (99%).
CONCLUSIONS:
Positive predictive validity of the ASAS criteria for axSpA (including both arms) at 5 years was excellent; it is worth noting that the performances of the other criteria were also very good in the DESIR cohort.